URGN vs NUVL

Analysts rate UroGen Pharma Ltd.

(URGN) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to +45. 9% for UroGen Pharma Ltd. (URGN). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus URGN's +90. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nuvalent, Inc.

(NUVL) is the lower-risk stock at 1. 09β versus UroGen Pharma Ltd. 's 1. 88β — meaning URGN is approximately 73% more volatile than NUVL relative to the S&P 500.

On earnings-per-share growth, the picture is similar: UroGen Pharma Ltd.

grew EPS -7. 8% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Nuvalent, Inc.

(NUVL) is the more profitable company, earning 0. 0% net margin versus -139. 8% for UroGen Pharma Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NUVL leads at 0. 0% versus -113. 7% for URGN. At the gross margin level — before operating expenses — URGN leads at 88. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Nuvalent, Inc.

(NUVL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09), +446. 1% 10Y return). UroGen Pharma Ltd. (URGN) carries a higher beta of 1. 88 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NUVL: +446. 1%, URGN: +90. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: URGN is a small-cap high-growth stock; NUVL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.